Back to search

University of South Florida

IFNγ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

Abstract

dc:description

CAR-T therapy has improved overall and complete response rates, andprolonged progression free survival of patients with relapsed/refractory hematological malignancies. The short-term and long-term impacts of anti-CD19 CAR-T products on the immune landscape of B cell malignancies has garnered considerable attention in recent years. Most notably, a subset of patients experience high-grade cytokine toxicities, including cytokine release syndrome and immune cell-associated hematologic toxicity that manifest as prolonged cytopenia. Whereas etiology of CRS is more well established, the mechanisms leading to CAR-T associated cytopenia remains elusive. Rejeski et. al. showed that severe cytopenia in patients post CAR-T treatment led to frequent infections and increased hospitalizations. Onset of cytopenia was associated with worse survival owing to non-relapse mortality in patients post CAR-T treatment, thereby emphasizing the need to address these hematological toxicities. An observation drawn from two independent clinical trials was the co-occurrence of cytopenia with CRS. Among the cytopenias neutropenia was most predominant, where the decline in neutrophils intensified with the grade of CRS. We utilized an IL-2Rα knockout mouse model to recapitulate cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to a disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils, and adecrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ- ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated both CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive cooccurrence of CRS and neutropenia in an IFNγ-dependent manner, leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (Ph.D.)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Biology (Cell Biology, Microbiology, Molecular Biology)
Grantor
University of South Florida
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Goala, Payal
Contributors dc:contributor
  • Marco L. Davila,MD, Ph.D.
  • Michael D. Jain,MD, Ph.D.
  • Paulo Rodriguez, Ph.D.
  • Jose Alejandro Guevara,MD, Ph.D.

Subjects

dc:subject × 10

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.usf.edu/etd/11293

Chain of custody

source
Harvested from
University of South Florida
Base URL
digitalcommons.usf.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Goala, Payal. IFNγ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. Dissertation thesis, University of South Florida, 2025. https://digitalcommons.usf.edu/etd/11293